In response to the Office Action dated January 10, 2008 (Paper No. 20080104), please amend the above-identified application as follows:

a.) Amendment to the Claims

Claims 1-10 (Cancelled).

11. (Currently Amended) A benzoyl compound represented by ~~general~~ formula (IA):



(IA)

[wherein

nA represents an integer of 1 to 5;

R^{1A} represents substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkoxy, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkoxycarbonyl, substituted or unsubstituted heterocyclic alkyl, substituted or unsubstituted aryl, $CONR^7R^8$ (wherein R^7 and R^8 independently represent a hydrogen atom, substituted or unsubstituted lower alkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted lower alkanoyl, substituted or unsubstituted aryl, a substituted or unsubstituted heterocyclic group, substituted or unsubstituted aralkyl, substituted or unsubstituted heterocyclic alkyl, or substituted or unsubstituted aroyl, or R^7

and R^8 form a substituted or unsubstituted heterocyclic group together with the adjacent nitrogen atom) or NR^9R^{10} (wherein R^9 and R^{10} have the same meanings as the above R^7 and R^8, respectively);

R^{2A} represents substituted or unsubstituted aryl;

~~R^{3A} and R^{5A}~~ R^{3A}, R^{4A} and R^{5A} each represent a hydrogen atom; and

~~R^{4A} represents a hydrogen atom; and~~

R^{6A} represents ~~a hydrogen atom,~~ halogen, lower alkyl or aryl~~; provided that:~~

~~when R^{6A} is a hydrogen atom, and $-(CH_2)_{nA}R^{1A}$ is~~

~~(a) 2-(acetoxymethyl)heptyl, 3-oxopentyl or pentyl,~~

~~R^{2A} is not 6-hydroxy-4-methoxy-3-methoxycarbonyl-2-pentylphenyl,~~

~~(b) 3-oxopentyl,~~

~~R^{2A} is not a group selected from the group consisting of 3-benzyloxycarbonyl-6-hydroxy-4-methoxy-2-pentylphenyl and 3-carboxy-6-hydroxy-4-methoxy-2-pentylphenyl, and~~

~~(c) n-propyl,~~

~~R^{2A} is not 2,4 dihydroxy 6 [(4 hydroxy 2 oxopyran 6 yl)methyl]phenyl~~],

or a pharmaceutically acceptable salt thereof.

12. (Previously Presented) The benzoyl compound according to claim 11, wherein R^{2A} is substituted aryl having 1 to 3 substituents, or aryl, or a pharmaceutically acceptable salt thereof.

Claims 13 and 14 (Cancelled).

15. (Previously Presented) The benzoyl compound according to claim 11 or 12, wherein R^{1A} is $CONR^{7}R^{8}$, or a pharmaceutically acceptable salt thereof.

16. (Previously Presented) The benzoyl compound according to claim 11 or 12, wherein R^{6A} is lower alkyl, or a pharmaceutically acceptable salt thereof.

17. (Previously Presented) A pharmaceutical composition comprising, as an active ingredient, the benzoyl compound according to claim 16 or a pharmaceutically

acceptable salt of said benzoyl compound, together with a pharmaceutically acceptable carrier.

Claims 18-31 (Cancelled).

32. (Previously Presented) The benzoyl compound according to claim 11, wherein

nA is 1,

R^{1A} is $CONR^{7a}R^{8a}$ (wherein R^{7a} and R^{8a} independently represent lower alkyl substituted by hydroxyl or lower alkoxy), and

R^{6A} is lower alkyl,

or a pharmaceutically acceptable salt thereof.

33. (Previously Presented) The benzoyl compound according to claim 32, wherein R^{2A} is 

(wherein R^{2a} represents substituted or unsubstituted lower alkoxy, and R^{2b} represents substituted or unsubstituted heterocyclic-alkyl oxy), or a pharmaceutically acceptable salt thereof.

34. (Previously Presented) The benzoyl compound according to claim 32, wherein R^{2A} is 

(wherein R^{2a} represents substituted or unsubstituted lower alkoxy, and R^{2b} represents substituted or unsubstituted heterocyclic-alkyl oxy), or a pharmaceutically acceptable salt thereof.

35. (Previously Presented) The benzoyl compound according to claim 32, wherein R^{2A} is 

(wherein R^{2b1} represents substituted or unsubstituted morpholino or substituted or unsubstituted piperidino), or a pharmaceutically acceptable salt thereof.